Table 2.
Inflammatory Marker | At Risk, na | Follow-Up, % | Incident Cases, n | Cumulative Incidence, %b | Hazard Ratio (95% Confidence Interval) | ||
---|---|---|---|---|---|---|---|
Model 1c | Model 2d | Statin Nonuserse | |||||
Baseline CRP | n = 1,947 | n = 1,904 | n = 1,513 | ||||
Tertile 1 | 764 | 86.0 | 67 | 11.2 | Reference | Reference | Reference |
Tertile 2 | 760 | 87.2 | 54 | 9.1 | 0.72 (0.49–1.06) | 0.72 (0.48–1.08) | 0.85 (0.53–1.35) |
Tertile 3 | 763 | 82.3 | 57 | 10.7 | 0.92 (0.63–1.36) | 0.83 (0.55–1.25) | 0.83 (0.52–1.34) |
Baseline IL-6 | n = 1,947 | n = 1,904 | n = 1,513 | ||||
Tertile 1 | 762 | 92.5 | 59 | 9.0 | Reference | Reference | Reference |
Tertile 2 | 762 | 86.0 | 63 | 10.9 | 0.89 (0.61–1.31) | 0.96 (0.64–1.42) | 0.96 (0.61–1.51) |
Tertile 3 | 763 | 77.1 | 56 | 11.6 | 0.99 (0.67–1.48) | 0.95 (0.62–1.45) | 0.95 (0.59–1.54) |
Baseline TNF- α | n = 1,947 | n = 1,904 | n = 1,513 | ||||
Tertile 1 | 653 | 99.9f | 60 | 10.1 | Reference | Reference | Reference |
Tertile 2 | 643 | 100.0f | 50 | 8.7 | 0.75 (0.50–1.12) | 0.73 (0.49–1.11) | 0.65 (0.41–1.04) |
Tertile 3 | 655 | 99.7f | 68 | 12.3 | 0.82 (0.56–1.21) | 0.78 (0.53–1.15) | 0.68 (0.43–1.06) |
10-year CRP | n = 1,941 | n = 1,899 | n = 1,470 | ||||
Low-low | 378 | 88.6 | 38 | 12.5 | Reference | Reference | Reference |
All other | 1,402 | 86.0 | 110 | 10.2 | 0.80 (0.54–1.20) | 0.74 (0.49–1.13) | 0.74 (0.46–1.19) |
High-high | 500 | 80.4 | 29 | 8.9 | 0.57 (0.34–0.96) | 0.46 (0.26–0.80) | 0.41 (0.21–0.79) |
10-year IL-6 | n = 801 | n = 779 | n = 604 | ||||
Low-low | 222 | 93.2 | 10 | 5.4 | Reference | Reference | Reference |
All other | 573 | 82.9 | 57 | 13.6 | 1.75 (0.85–3.64) | 1.81 (0.85–3.87) | 1.93 (0.78–4.82) |
High-high | 164 | 72.6 | 14 | 16.5 | 2.35 (0.96–5.73) | 2.35 (0.90–6.14) | 3.35 (1.09–10.30) |
CRP= C-reactive protein; IL-6= interleukin-6.
Participants without cognitive impairment at baseline (1998–2000).
Cumulative incidence using Kaplan–Meier method.
Model 1 covariates: baseline age, sex, and education.
Model 2 covariates: Model 1 + smoking status, ever heavy drinking, Medical Outcomes Study 36-item Short-Form Health Survey Mental Component Subscale score, body mass index, and stroke.
For baseline categories, includes only participants reporting statin nonuse at baseline; for 10-year categories, includes only participants reporting statin nonuse at baseline and 5 and 10 years before baseline (Model 2 covariates).
Tumor necrosis factor alpha (TNF-α) was only measured in participants with some follow-up.